Sign inJoin waitlistJoin the waitlist

PH

Paul Hamlin

Professor of Clinical Medicine · New York Presbyterian Hospital

Credentials: · · · ·

History

New York Presbyterian Hospital
Present

Medical Oncology
2000–2002
Internal Medicine
1997–2000
SUNY Downstate University Health Sciences University College of Medicine
1993–1997

Research

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
Journal of Clinical Oncology · 2005 · 468 citations
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma
Cancer Discovery · 2017 · 324 citations
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
Journal of Clinical Oncology · 2010 · 271 citations

AZ
Andrew Zelenetz
75 papers
AN
Ariela Noy
55 papers
Craig Moskowitz
51 papers
SH
Steven Horwitz
48 papers
AM
Alison Moskowitz
46 papers · 1 as a fellow
AK
Anita Kumar
46 papers
DS
David Straus
44 papers
Matthew Matasar
43 papers
Lia Palomba
40 papers
CP
Carol Portlock
30 papers
Joachim Yahalom
30 papers
GS
Gilles Salles
28 papers

Clinical trials

Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy
Principal investigator · Active not recruiting
Memorial Sloan Kettering Cancer Center
2013–2027
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Principal investigator · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2011–2023
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
Study chair · Completed · Phase 2
Memorial Sloan Kettering Cancer Center
2003–2019